CONDUIT PHARMACEUTICALS INC.
4995 Murphy Canyon Road, Suite 300
San Diego, CA 92134
December 13, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Conduit Pharmaceuticals Inc. (the “Company”) |
| Registration Statement on Form S-1, as amended | |
| File No. 333-275056 (the “Registration Statement”) |
Dear Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement be declared effective by the Securities and Exchange Commission at 4:30 p.m., Eastern Time on December 15, 2023, or as soon as practicable thereafter.
Please call Todd Mason at (212) 908-3946 of Thompson Hine LLP to confirm the effectiveness of the Registration Statement or with any questions.
[Signature Page Follows]
| Sincerely, | ||
| CONDUIT PHARMACEUTICALS INC. | ||
| By: | /s/ David Tapolczay | |
| Name: | David Tapolczay | |
| Title: | Chief Executive Officer | |
